The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
 
Laurie Helen Sehn
Honoraria - Abbvie; Acerta Pharma; Amgen; Apobiologix; AstraZeneca; Celgene; Debiopharm Group; Genmab; Gilead Sciences; Incyte; Janssen-Ortho; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; morphosys; Roche/Genentech; Sandoz-Novartis; Seagen; Takeda; Teva; TG Therapeutics; Verastem
Consulting or Advisory Role - Abbvie; Acerta Pharma; Amgen; Amgen; apobiologix; AstraZeneca; Celgene; Debiopharm Group; Genmab; Gilead Sciences; Incyte; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; MorphoSys; Roche/Genentech; Sandoz-Novartis; Seagen; Takeda; Teva; TG Therapeutics; TG therapeutics; Verastem
Research Funding - Roche/Genentech (Inst); Teva (Inst)
 
Christian W Scholz
Consulting or Advisory Role - Roche (Inst)
 
Stefano Luminari
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Genmab (Inst); Janssen (Inst); Regeneron (Inst); Roche (Inst)
 
Antonio Salar
Speakers' Bureau - Celgene (Inst); Janssen (Inst); Roche (Inst)
Research Funding - Gilead Sciences (Inst)
 
Bjorn E. Wahlin
Consulting or Advisory Role - Roche (Inst)
Research Funding - Gilead Sciences (Inst)
 
Ajay K. Gopal
Honoraria - Actinium Pharmaceuticals; ADC Therapeutics; Amgen; Cellectar; Epizyme; Gilead Sciences; I-mab; Janssen Oncology; Kite/Gilead; Merck; morphosys; nurix; Pfizer; Seagen; Takeda; TG Therapeutics
Consulting or Advisory Role - Cellectar; Gilead Sciences; I-Mab; Incyte; Janssen Oncology; Kite/Gilead; Millennium; morphosys; nurix; Pfizer; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); I-Mab (Inst); IgM (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst)
 
Christophe Marc Bonnet
Consulting or Advisory Role - Roche
 
Shankara Paneesha
Honoraria - Celgene (Inst); Roche (Inst)
 
Oliver Manzke
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Francis Seguy
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Di Li
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Kai Hübel
Consulting or Advisory Role - Celgene (Inst); EUSA Pharma (Inst); Gilead Sciences (Inst); Incyte (Inst); Roche (Inst); SERVIER (Inst)
Speakers' Bureau - Celgene (Inst); EUSA Pharma (Inst); Gilead Sciences (Inst); Incyte (Inst); Roche (Inst); SERVIER (Inst)